<DOC>
	<DOCNO>NCT00136552</DOCNO>
	<brief_summary>The purpose study assess prospective multicentric study ( Phase III ) introduction monoclonal antibody direct B-cells associated standard therapy include chemotherapy alpha-interferon first line treatment patient large tumor burden follicular lymphoma .</brief_summary>
	<brief_title>Study Newly Diagnosed Follicular Lymphoma Patients With Large Tumor Burden</brief_title>
	<detailed_description>Follicular lymphoma patient large tumor burden randomize 18 month treatment either : - Arm A : CHVP + alpha2a-interferon . Patients receive 12 course CHVP ( cyclophosphamide 600 mg/m² , adriamycin 25 mg/m² , etoposide 100 mg/m² day 1 prednisolone 40 mg/m² 5 day ) , one course every month 6 month one course every month 12 additional month associate alpha2a-interferon 4.5 million unit sub-cutaneously three time week 18 month . - Arm B : CHVP + alpha2a-interferon + rituximab . Patients receive 6 monthly course CHVP ( cyclophosphamide 600 mg/m² , adriamycin 25 mg/m² , etoposide 100 mg/m² day 1 prednisolone 40 mg/m² 5 day ) associate 6 infusion rituximab ( 375 mg/m2 ) associate alpha2a-interferon 4.5 million unit sub-cutaneously three time week 18 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Histologically confirm follicular lymphoma biopsy perform last 3 month Patients previously untreated . Patients least one follow symptom require initiation treatment : Bulky disease study entry accord Groupe d'Etudes Lymphomes Folliculare ( GELF ) criterion : nodal extranodal mass &gt; 7cm great diameter B symptom Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) &gt; 1 Elevated serum lactate dehydrogenase ( LDH ) beta2microglobulin Involvement least 3 nodal site ( diameter great 3 cm ) Symptomatic splenic enlargement Compressive syndrome Pleural/peritoneal effusion Age must &gt; 18 year less 76 year Having previously sign write informed consent form . Transformation highgrade lymphoma ( secondary “ lowgrade ” follicular lymphoma ) . Patients without large tumor burden . Patients prior concomitant malignancy except nonmelanoma skin cancer adequately treat situ cervical cancer . Poor renal function : Serum creatinine &gt; 150 μmol/L , Known HIV infection active hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection . Patients contraindication interferon , adriamycin , rituximab . Serious underlie medical condition , could impair ability patient participate trial ( e.g . ongoing infection , uncontrolled diabetes mellitus , gastric ulcer , active autoimmune disease ) . Judgment investigator . Known sensitivity allergy murine product Adult patient tutelage .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>lymphoma</keyword>
	<keyword>follicular</keyword>
	<keyword>B-cell</keyword>
	<keyword>rituximab</keyword>
	<keyword>interferon</keyword>
</DOC>